Poor
Not Aligned
Patient Risk:
Medium
Summary
Only a subset of claims are supported by the provided label excerpts (active ingredient and MDD indication in adults). Multiple mechanism/pharmacologic receptor statements and several side-effect/class-comparator/market-origin claims are unsupported or not supported by the provided label text, leading to poor overall alignment.
Category Scores
Accurate Statements
The active ingredient of Trintellix is vortioxetine.
Supported by 11 DESCRIPTION (vortioxetine HBr equivalent to vortioxetine).
Trintellix is a prescription medication used to treat major depressive disorder (MDD) in adults.
Supported by 1 INDICATIONS AND USAGE (indicated for MDD in adults).
Serious side effects of Trintellix can include suicidal thoughts or behaviors.
Supported in part by 6 ADVERSE REACTIONS and the boxed WARNING text (suicidal thoughts and behaviors; also notes not approved for pediatric).
Serious side effects of Trintellix can include serotonin syndrome.
Supported in part by 6 ADVERSE REACTIONS (Serotonin Syndrome) and 5 WARNINGS AND PRECAUTIONS heading presence in provided excerpt.
Serious side effects of Trintellix can include increased bleeding risk.
Supported in part by 6 ADVERSE REACTIONS (Increased Risk of Bleeding).
Unsupported Statements
A generic version of Trintellix is not currently available in the United States.
Not supported by the provided label excerpts; appears to be an external market/supply claim.
Trintellix is still under patent protection.
Not supported by the provided label excerpts.
Trintellix works by affecting chemical messengers in the brain, including serotonin.
Mechanism claim not supported by the provided label excerpts.
Vortioxetine is a serotonin (5-HT) reuptake inhibitor that increases the availability of serotonin in the synaptic cleft.
Not supported by the provided label excerpts.
Vortioxetine modulates the activity of various serotonin receptors.
Not supported by the provided label excerpts.
Vortioxetine acts as an agonist at the 5-HT1A receptor.
Not supported by the provided label excerpts.
Vortioxetine acts as an antagonist at the 5-HT3 receptor.
Not supported by the provided label excerpts.
Vortioxetine acts as an antagonist at the 5-HT7 receptor.
Not supported by the provided label excerpts.
Vortioxetine acts as a partial agonist at the 5-HT1B receptor.
Not supported by the provided label excerpts.
Common side effects of Trintellix include nausea.
Provided adverse-reaction excerpt lists warnings/precautions topics but does not substantiate this specific 'common side effect' detail in the supplied text.
Common side effects of Trintellix include vomiting.
Not substantiated as a 'common side effect' by the supplied adverse-reaction excerpt.
Common side effects of Trintellix include constipation.
Not substantiated as a 'common side effect' by the supplied adverse-reaction excerpt.
Common side effects of Trintellix include diarrhea.
Not substantiated as a 'common side effect' by the supplied adverse-reaction excerpt.
Trintellix belongs to a class of antidepressants that affect serotonin.
Although vortioxetine is described as an antidepressant, the supplied label excerpt does not support this specific 'class affecting serotonin' framing.
Other antidepressants similar to Trintellix include selective serotonin reuptake inhibitors (SSRIs).
Not supported by the provided label excerpts.
Other antidepressants similar to Trintellix include serotonin-norepinephrine reuptake inhibitors (SNRIs).
Not supported by the provided label excerpts.
Fluoxetine is an example of an SSRI.
Not supported by the provided label excerpts.
Sertraline is an example of an SSRI.
Not supported by the provided label excerpts.
Venlafaxine (Effexor XR) is an example of an SNRI.
Not supported by the provided label excerpts.
Duloxetine (Cymbalta) is an example of an SNRI.
Not supported by the provided label excerpts.
Trintellix is manufactured by Takeda Pharmaceuticals.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Dosage and administration details (e.g., dosing regimen, dose adjustments, administration instructions) that could materially affect label-alignment evaluation of dosing-related claims.
Importance:
Moderate
Contraindications, detailed warnings/precautions beyond the provided boxed WARNING text, and drug interaction specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several mechanism/receptor and 'common side effects' claims are unsupported by the provided label text, which can mislead about drug pharmacology and frequency of adverse effects. While some serious boxed/warning-linked events are supported, overall label adherence is poor based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported pharmacologic mechanism, receptor-binding, side-effect frequency, comparative antidepressant/class, and manufacturer/market-status claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported information from the provided sections (e.g., indication in adults, vortioxetine as active ingredient, and the boxed warning/serious adverse events explicitly listed). Remove or re-cite receptor-mechanism and specific 'common side effect' frequency statements unless supported by the corresponding label portions.